Detalimogene interim data supports 2027 U.S. approval push
Detalimogene, a non-viral gene therapy for BCG-unresponsive NMIBC, is advancing toward a 2027 U.S. approval supported by interim efficacy, safety and ease-of-use data.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.